Is Aspirin Safe for Thromboprophylaxis After Surgery for Lower Extremity Neoplastic Pathologic Fractures?
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.27997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Matthew S Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Keck School of Medicine of USC, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Aspirin, Venous Thromboembolism, Postoperative Complications, Lower Extremity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background and Objectives Both malignancy and orthopedic surgery are known risk factors for developing venous thromboembolism (VTE). Therefore, this study aimed to compare VTE rates among patients receiving enoxaparin, apixaban, rivaroxaban, or aspirin (ASA).
Methods
The Premier Healthcare Database was utilized to identify all patients who underwent surgery for neoplastic pathologic fractures of the lower extremities from 2015 to 2021. Four cohorts based on receipt of ASA, apixaban, enoxaparin, or rivaroxaban were identified. Propensity matching with the enoxaparin cohort as the comparator was performed. Patient demographics, hospital factors, comorbidities, and 90‐day complications were compared.
Results
From 2015 to 2021, 3762 patients underwent surgical intervention for neoplastic pathologic fracture of the lower extremities. Enoxaparin recipients showed significantly lower aggregate VTE rates than those on apixaban ( p = 0.008) while exhibiting higher VTE occurrence than ASA‐treated patients ( p = 0.050).
Conclusion
Our study demonstrates that the administration of enoxaparin in patients undergoing surgical intervention for neoplastic pathologic fractures of the lower extremities may lead to significantly higher rates of aggregate VTE postoperatively compared to ASA. This data suggests that further research is warranted to determine if surgeons may safely consider using ASA in patients with no other reported risk factors or need for anticoagulation postoperatively, even in active malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Keck School of Medicine of USC, Los Angeles, California, USA.
- University of South Carolina School of Medicine, Columbia, South Carolina, USA.
- Kansas City University College of Osteopathic Medicine, Kansas City, Missouri, USA.
- Department of Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, USA.
- Department of Surgery, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Zitieren
APA
Chen, M. S., Gettleman, B. S., Liu, K. C., Richardson, M. K., Talehakimi, A., Heckmann, N. D., Menendez, L., & Christ, A. B. (2025). Is Aspirin Safe for Thromboprophylaxis After Surgery for Lower Extremity Neoplastic Pathologic Fractures?. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27997
Vancouver
Chen MS, Gettleman BS, Liu KC, Richardson MK, Talehakimi A, Heckmann ND, et al. Is Aspirin Safe for Thromboprophylaxis After Surgery for Lower Extremity Neoplastic Pathologic Fractures?. Journal of Surgical Oncology. 2025. doi:10.1002/jso.27997
BibTeX
@article{Chen2025,
author = {Chen, Matthew S and Gettleman, Brandon S and Liu, Kevin C and Richardson, Mary K and Talehakimi, Arad and Heckmann, Nathanael D and Menendez, Lawrence and Christ, Alexander B},
title = {Is Aspirin Safe for Thromboprophylaxis After Surgery for Lower Extremity Neoplastic Pathologic Fractures?},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.27997}
}
EUVIMED